《大行報告》匯豐研究下調中燃(00384.HK)目標價至32元 評級「買入」
匯豐研究發表報告表示,中燃(00384.HK)截至今年3月底止年度核心利潤按年升9%至103億元,低於市場及管理層預期;全年業績由燃氣貢獻所帶動,主因市場需求上升令銷氣量升逾20%。
報告又指,集團指引2022財年銷氣量增長15%至20%,固定邊際利潤(dollar margin)維持於0.6元人民幣以上,而新接駁用戶指引則按年持平於500萬。
該行下調中燃2022至2023財年之盈利預測分別9.6%及8.9%,目標價由35元降至32元;惟認爲基於其目前估值、風險回報率爲行業中最具吸引力,故維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.